AMGN · Earnings call · 2026Q3T · Full report

Revenue Performance and Mix

AMGEN INC · 2026-11-03 · Importance 49 · Surprise 32 · No source text

Third-quarter 2026 total revenue and product sales each grew 8% year over year; total revenue was $10.4 billion. Amgen’s six key growth drivers grew 27% and accounted for more than 70% of product sales, while 17 products delivered double-digit growth and 17 were annualizing at more than $1 billion in sales. Repatha sales rose 37% to $1.1 billion, EVENITY rose 39% to $751 million, and TEZSPIRE rose 43% to $538 million. The rare disease portfolio grew 21% to $1.6 billion, including UPLIZNA up 191% to $451 million; innovative oncology grew 21% to $2.1 billion, while biosimilar sales grew 26% to $977 million.

Key facts

• Amgen's 6 key growth drivers grew 27% year-over-year and represented over 70% of Q3 2026 product sales.
• Amgen's 6 key growth drivers all delivered double-digit growth in Q3 2026, growing 27% year-over-year and representing more than 70% of product sales.
• Amgen Q3 2026 total revenues grew 8% year-over-year to $10.4 billion.
• Amgen reported Q3 2026 product sales growth of 8% year-over-year and had 17 products annualizing at more than $1 billion in sales.
• In Q3 2026, 17 Amgen products delivered double-digit sales growth and 17 products were annualizing at more than $1 billion based on quarterly sales.

Impact estimates